Zhongguancun Shuimu Medical
A third-party professional medical device inspection and testing institution
About Zhongguancun Shuimu Medical
Zhongguancun Shuimu Medical Technology Service Group, established in October 2017, operates as a pivotal service provider within China's medical device sector. The company was founded by Sun Jingsheng, who brings profound regulatory and technical experience from his previous roles, including serving as the director of the medical device registration and supervision department at the former Beijing Food and Drug Administration. This background provides the firm with a deep understanding of the industry's complex regulatory landscape, positioning it to address a critical market need.
The firm's business model is centered on providing a comprehensive, one-stop service platform for medical device companies, aiming to streamline the path from development to market launch. It addresses what founder Sun Jingsheng identifies as a major challenge for domestic manufacturers: navigating China's stringent regulatory standards, which have rapidly aligned with international levels, while the industry's development capabilities still lag. Zhongguancun Shuimu Medical generates revenue by offering an integrated suite of services that spans the entire product lifecycle. This solves the "last mile" problem for innovators struggling with industrialization and compliance.
The company's service portfolio is extensive, functioning as a contract research organization (CRO) and a contract development and manufacturing organization (CDMO). Key service platforms include: engineering design and evaluation, inspection and testing, clinical trial management, global registration, and CDMO services. The firm also has a specialized platform for the R&D and production of In-Vitro Diagnostic (IVD) standards and quality control products. This end-to-end model is designed to support clients, who are primarily innovative medical device and IVD companies, through every stage, including concept research, prototype production, clinical trials, and supply chain management. By bundling these often-fragmented services, the company helps clients reduce risks, improve efficiency, and accelerate their product's time to market.
Since its inception, the company has achieved notable milestones, including being recognized as the first privately-owned third-party professional medical device inspection and testing institution in China. By the end of 2021, it had served over 200 clients, focusing on high-end medical devices such as advanced therapeutic instruments and novel diagnostic reagents. A significant financing event occurred in July 2022, when the company secured an A+ funding round in the hundred-million yuan class to expand its CDMO and animal testing capabilities, further solidifying its all-encompassing service platform.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Hard Tech, Health It, medical testing
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2025 | $28M | $110M | Chengdu Bio-Town Investment · Guangzhou Industrial Investment Group · Hony Capital · Guoju Venture Capital | ↗ |
| SERIES AEquity / VC | Jul 2022 | $14M | $55M | Yijing Capital | ↗ |
Growth signals
Latest recorded traffic for Zhongguancun Shuimu Medical is 940 monthly website visits, up 526.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhongguancun Shuimu Medical in the Dongcheng District ecosystem
The Zhongguancun Shuimu Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Med-Fine Capital
Yijing Capital- HCHony Capital
- GCGuoju Venture Capital
- CIChengdu Bio-Town Investment
- GGGuangzhou Industrial Investment Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhongguancun Shuimu Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhongguancun Shuimu Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








